Search - tctmd.com

Displaying 201 - 220 of 445

Sort: Relevancy | Date

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

Todd Neale

October 18, 2016

News Daily News

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Shelley Wood

October 03, 2016

News Daily News

MATRIX: No Hay Diferencias entre Bivalirudina y Heparina No Fraccionada en Pacientes SCA Con o Sin Elevación del Segmento ST

Shelley Wood

October 03, 2016

News Daily News

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Caitlin E. Cox

September 08, 2016

News Daily News

Las Tendencias en el Desarrollo de Fármacos Cardiovasculares Indican Problemas y Posibilidades Durante la Fase de Desarrollo

Caitlin E. Cox

September 08, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Industry News

Armetheon Announces Positive Results of Pharmacokinetics Study of Tecarfarin versus Warfarin

August 25, 2016

News Daily News

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

Michael O'Riordan

August 24, 2016

News Daily News

Another Meta-Analysis Supports Prolonged Bivalirudin Use in STEMI, but Is Contemporary PCI Reflected?

Yael L. Maxwell

July 27, 2016

News Daily News

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

Michael O'Riordan

July 21, 2016

News Daily News

La Infrautilización del Tratamiento Médico se asocia a Más Episodios Adversos en Pacientes Muy Ancianos

Michael O'Riordan

July 21, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

News Daily News

Could Biased Medication Prescribing Explain Obesity Paradox in PCI?

L.A. McKeown

May 19, 2016

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

Advertisement

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

TCTMD’s Top 10 Most Popular Stories for October 2016

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

MATRIX: No Hay Diferencias entre Bivalirudina y Heparina No Fraccionada en Pacientes SCA Con o Sin Elevación del Segmento ST

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Las Tendencias en el Desarrollo de Fármacos Cardiovasculares Indican Problemas y Posibilidades Durante la Fase de Desarrollo

TCTMD’s Top 10 Most Popular Stories for August 2016

Armetheon Announces Positive Results of Pharmacokinetics Study of Tecarfarin versus Warfarin

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

Another Meta-Analysis Supports Prolonged Bivalirudin Use in STEMI, but Is Contemporary PCI Reflected?

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

La Infrautilización del Tratamiento Médico se asocia a Más Episodios Adversos en Pacientes Muy Ancianos

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Could Biased Medication Prescribing Explain Obesity Paradox in PCI?

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content